Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ).
Cizzle Biotechnology Holdings PLC has raised £150,000 through a convertible loan note to support the expansion of its CIZ1B early cancer test in the UK and Europe. This funding follows a successful licensing agreement in North America and aims to accelerate the company’s growth strategy, improving early cancer diagnosis and potentially saving lives by reducing premature cancer deaths.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based company specializing in the development of diagnostic tests for early cancer detection. Their primary product is the CIZ1B biomarker test, a non-invasive, cost-effective blood test aimed at the early detection of lung cancer. The company focuses on licensing its technology globally and has established partnerships with clinical laboratories and hospitals to enhance market penetration.
Average Trading Volume: 523,689
Technical Sentiment Signal: Sell
Current Market Cap: £5.95M
For an in-depth examination of CIZ stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue